Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
Holding NMRA?
Track your performance easily
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.83 - $21.00
Previous CloseN/A
Volume2.95M
Average Volume (3M)4.35M
Market Cap
$368.36M
Enterprise Value$1.77B
Total Cash (Recent Filing)$371.88M
Total Debt (Recent Filing)$5.07M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 06, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding161,561,070
10 Day Avg. Volume11,197,789
30 Day Avg. Volume4,354,174
Standard Deviation0.21
R-Squared0.21
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap4.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.78
Forecast
1Y Price Target
$16.00Price Target Upside637.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Neumora Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSafety and tolerability for navacaprant have been excellent so far, with no significant side effects reported, which is considered ideal for trial success.
Financial PerformanceThe company is well funded with $342M in cash—more than enough to complete the KOASTAL program and pursue additional work to bring navacaprant to market.
Market PotentialThe oral pill form of navacaprant, depending on reimbursement, could lead to quick uptake among prescribers.
Bears Say
Clinical TrialsNMRA announced negative first P3 KOASTAL-1/K-1 study data for navacaprant in major depressive disorder/MDD, with navacaprant missing on both primary and secondary endpoints.
Market PerceptionThere is a perception that the KOASTAL-2/3 trials are very high-risk.
Stock PerformanceRecent share weakness, with NMRA shares down 33% since a recent high, is attributed to potential market disappointment over the timing of data announcements.
---
Ownership Overview
26.13% Insiders
7.59% Mutual Funds
2.05% Other Institutional Investors
58.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $1.83 and its highest was $21.00 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $368.36M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.059.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.44.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,561,070 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -17.082%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Among the largest hedge funds holding Neumora Therapeutics, Inc.’s share is Baker Bros Advisors LP. It holds Neumora Therapeutics, Inc.’s shares valued at 14M.
---
Neumora Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (637.33% Upside)
$16.00 (637.33% Upside)
Blogger Sentiment
Neutral
NMRA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 246.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 33.7%
Last 30 Days ▲ 33.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.55%
12-Months-Change
Fundamentals
Return on Equity
-70.48%
Trailing 12-Months
Asset Growth
-35.28%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
---
NMRA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Neumora's robust clinical pipeline and financial position, with promising developments in their lead program, Navacaprant. However, increased operating expenses and the inherent challenges in CNS drug development were noted.Read More>---
NMRA Stock 12 Month Forecast
Average Price Target
$16.00
▲(637.33% Upside)
Technical Analysis
Axsome Therapeutics
―
SAGE Therapeutics
―
Prothena
―
ACADIA Pharmaceuticals
―
Cytokinetics
―
Vaxart
―
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-37.78%
reiterated a buy rating 16 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -37.78% per trade.
---